Lixte Biotech Hldgs (LIXT) 0.2600 $LIXT
Neurofibromatoses Type II Therapeutics Pipeline Review 2015 - 4 Companies & 6 Drug Profiles
M2 - Thu Jun 25, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9gp7cv/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arno Therapeutics, Inc. - CalAsia Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - Lixte Biotechnology Holdings, Inc. Drug Profiles - AR-42 - FRAX-597 - LB-201 - LB-205 - NXD-30001 - Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2 For more information visit http://www.researchandmarkets.com/research/9g...bromatoses
Septic Shock Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Tue Jun 16, 5:31AM CDT
The report "Septic Shock - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Septic Shock. Septic shock is life-threatening low blood pressure (shock) due to sepsis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Septic Shock with 30 market data tables and 14 figures, spread across 77 pages is available at http://www.rnrmarketresearch.com/septic-shock...eport.html .
CGEN: 6.63 (+0.06)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 0.28 (unch), CNCE: 15.71 (+0.27), ATHX: 1.14 (-0.01), KPTI: 25.57 (+0.24), CUR: 1.69 (-0.01)
Myocardial Ischemia - Pipeline Review, H1 2015 - 8 Companies & 22 Drug Profiles
M2 - Wed Mar 25, 12:05PM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc6lt6/myocardial) has announced the addition of the "Myocardial Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - CoDa Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Miltenyi Biotec GmbH - Nyken BV - Opsona Therapeutics Ltd. - Taxus Cardium Pharmaceuticals Group Inc. - ViroMed Co., Ltd. Drug Profiles - alferminogene tadenovec - AntimiR-199a - EP-80317 - Gene Therapy for Ischemic Heart Failure - Humanin - LB-100 - LB-102 - MG-53 - NYK-1112 - OPN-305 - Peptagon - PMC-6 - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology - Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Stem Cell Therapy for Cardiovascular Disease - Stem Cell Therapy for Cardiovascular Diseases - VM-202 For more information visit http://www.researchandmarkets.com/research/sc6lt6/myocardial
BAX: 37.61 (+0.59)
Lixte Completes Private Placement Of Convertible Preferred Stock
PR Newswire - Wed Mar 18, 8:04AM CDT
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that one of its major shareholders has purchased $1,750,000 of Convertible Preferred stock. If fully converted, these shares would convert to 2,187,500 common shares at a per share price of $0.80.
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
PR Newswire - Fri Jan 23, 8:04AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of clinical sites where its Phase I trial of Lixte's lead compound, LB--100, is being conducted, has been expanded from 1 to 5 institutions.
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.20 (+0.24), AMGN: 154.10 (+2.79), RGLS: 10.14 (+0.30), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), PVCT: 0.51 (+0.01), CANF: 2.00 (+0.09), DCTH: 0.84 (unch), NVS: 103.22 (+3.20), XLRN: 30.03 (+0.20)
Brain Ischemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttpc9j/brain_ischemia) has announced the addition of the "Brain Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Edge - FibroGen - Immune - Lixte Biotechnology Holdings, - Medestea Research & Production - NeuroNascent, - NeurOp - Spectrum - Sylentis - The International Biotechnology Center (IBC) For more information visit http://www.researchandmarkets.com/research/tt...n_ischemia
Lixte Biotech: A Novel Approach to Boost Existing Cancer Therapies
ACCESSWIRE - Tue Nov 18, 10:05AM CST
WHITEFISH, MT / ACCESSWIRE / November 18, 2014 / Cellular signaling is a complex system of communication that governs basic cellular activities and coordinates cell actions. In many cases, errors in cellular information processing are responsible for diseases like cancer, autoimmune disorders, and diabetes. Researchers are attempting to understand these cellular signaling pathways to effectively treat these disorders and accomplish other medical feats.
SGEN: 47.09 (+0.57)
Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
PR Newswire - Thu Nov 06, 9:00AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer, has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its lead compound, LB-100. For more information, see: http://www.iirusa.com/therapeuticareapartners...ingcos.xml
Neurofibromatoses Type II Therapeutics Pipeline Review 2015 - 4 Companies & 6 Drug Profiles
M2 - Thu Jun 25, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9gp7cv/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arno Therapeutics, Inc. - CalAsia Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - Lixte Biotechnology Holdings, Inc. Drug Profiles - AR-42 - FRAX-597 - LB-201 - LB-205 - NXD-30001 - Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2 For more information visit http://www.researchandmarkets.com/research/9g...bromatoses
Septic Shock Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Tue Jun 16, 5:31AM CDT
The report "Septic Shock - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Septic Shock. Septic shock is life-threatening low blood pressure (shock) due to sepsis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Septic Shock with 30 market data tables and 14 figures, spread across 77 pages is available at http://www.rnrmarketresearch.com/septic-shock...eport.html .
CGEN: 6.63 (+0.06)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 0.28 (unch), CNCE: 15.71 (+0.27), ATHX: 1.14 (-0.01), KPTI: 25.57 (+0.24), CUR: 1.69 (-0.01)
Myocardial Ischemia - Pipeline Review, H1 2015 - 8 Companies & 22 Drug Profiles
M2 - Wed Mar 25, 12:05PM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc6lt6/myocardial) has announced the addition of the "Myocardial Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - CoDa Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Miltenyi Biotec GmbH - Nyken BV - Opsona Therapeutics Ltd. - Taxus Cardium Pharmaceuticals Group Inc. - ViroMed Co., Ltd. Drug Profiles - alferminogene tadenovec - AntimiR-199a - EP-80317 - Gene Therapy for Ischemic Heart Failure - Humanin - LB-100 - LB-102 - MG-53 - NYK-1112 - OPN-305 - Peptagon - PMC-6 - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology - Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Stem Cell Therapy for Cardiovascular Disease - Stem Cell Therapy for Cardiovascular Diseases - VM-202 For more information visit http://www.researchandmarkets.com/research/sc6lt6/myocardial
BAX: 37.61 (+0.59)
Lixte Completes Private Placement Of Convertible Preferred Stock
PR Newswire - Wed Mar 18, 8:04AM CDT
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that one of its major shareholders has purchased $1,750,000 of Convertible Preferred stock. If fully converted, these shares would convert to 2,187,500 common shares at a per share price of $0.80.
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
PR Newswire - Fri Jan 23, 8:04AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of clinical sites where its Phase I trial of Lixte's lead compound, LB--100, is being conducted, has been expanded from 1 to 5 institutions.
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.20 (+0.24), AMGN: 154.10 (+2.79), RGLS: 10.14 (+0.30), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), PVCT: 0.51 (+0.01), CANF: 2.00 (+0.09), DCTH: 0.84 (unch), NVS: 103.22 (+3.20), XLRN: 30.03 (+0.20)
Brain Ischemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttpc9j/brain_ischemia) has announced the addition of the "Brain Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Edge - FibroGen - Immune - Lixte Biotechnology Holdings, - Medestea Research & Production - NeuroNascent, - NeurOp - Spectrum - Sylentis - The International Biotechnology Center (IBC) For more information visit http://www.researchandmarkets.com/research/tt...n_ischemia
Lixte Biotech: A Novel Approach to Boost Existing Cancer Therapies
ACCESSWIRE - Tue Nov 18, 10:05AM CST
WHITEFISH, MT / ACCESSWIRE / November 18, 2014 / Cellular signaling is a complex system of communication that governs basic cellular activities and coordinates cell actions. In many cases, errors in cellular information processing are responsible for diseases like cancer, autoimmune disorders, and diabetes. Researchers are attempting to understand these cellular signaling pathways to effectively treat these disorders and accomplish other medical feats.
SGEN: 47.09 (+0.57)
Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
PR Newswire - Thu Nov 06, 9:00AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer, has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its lead compound, LB-100. For more information, see: http://www.iirusa.com/therapeuticareapartners...ingcos.xml
